2026– date –
-
UZEDY: Teva’s risperidone real-world data and cost specs
Teva (Press Release) Israel Overview Teva announced new real-world data at Psych Congress 2026, demonstrating that UZEDY® (risperidone extended-release injectable) for schizophrenia significantly improved treatment adherence and reduced ... -
Enicepatide: Roche’s Phase II results for diabetes and obesity
Roche Switzerland Overview On September 22, 2026, Roche announced positive topline Phase II results for its once-weekly dual GLP-1/GIP receptor agonist, enicepatide (CT-388), in adults with type 2 diabetes and overweight or obesity. The ... -
SORT LNPs explained: Novel 5th lipid component for organ delivery
Patsnap Singapore Overview Patsnap's September 18, 2026 analysis highlights Selective Organ Targeting (SORT) Lipid Nanoparticles (LNPs) as a groundbreaking technology for highly efficient, organ-specific delivery of nucleic acid payloads... -
FDA: Non-animal testing standard roadmap and 2030 timeline
Vertex AI Search USA Overview The FDA announced plans to remove animal testing references from drug regulations, clarifying that companies can seek drug approval without animal data. This pivotal shift encourages the use of alternative m... -
Sotyktu: Bristol Myers Squibb’s first oral TYK2 inhibitor FDA specs
MarketBeat USA Overview Bristol Myers Squibb (BMS) announced FDA approval on March 6, 2026, for Sotyktu® (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of active psoriatic arthritis in adults. ... -
Elunetirom: Phase 2 AMPLIFY-BD trial results for bipolar depression
Pharmacally International Overview Elunetirom demonstrated favorable results in the Phase 2 AMPLIFY-BD open-label trial for bipolar depression, significantly reducing depressive symptoms and improving patient function. In 21 adults with ... -
LUNAR 2.0: Arcturus Therapeutics mRNA expression roadmap
Morningstar USA Overview Arcturus Therapeutics announced interim Phase 2 results for ARCT-810 in OTC Deficiency and unveiled its next-generation mRNA delivery platform, LUNAR 2.0™. ARCT-810 demonstrated a favorable safety profile and pro... -
mRNA Vaccine LNP: South Korea’s 2026 organ targeting specs
Vertex AI Search South Korea Overview In South Korea, new lipid nanoparticle (LNP) strategies for mRNA vaccines are being developed, including Selective Organ Targeting (SORT) to lung, spleen, and lymph nodes, and ligand conjugation to L... -
AI drug discovery: 80-90% Phase I success rate explained
World Health Expo International Overview AI-identified drug candidates have demonstrated an impressive 80-90% success rate in Phase I clinical trials, significantly surpassing the historical industry average. This breakthrough is driven ... -
Orforglipron: Eli Lilly oral GLP-1 vs injectable efficacy
Apps Script USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, has shown potent weight loss and glycemic control effects in early clinical trials comparable to injectable GLP-1 drugs for type 2 diabetes a...
